title: [Early diagnosis of prostate cancer in patients with prostate symptoms by DRE, PSA, TRU and DPSA].
abstract: Presentation of our experience in the early diagnosis of prostate cancer in patients with signs and symptoms of prostatism. Over a one year period (96-97), 316 patients underwent biopsy based on clearly defined criteria according to the diagnostic algorithm used in our centre: suspicious DRE and/or PSA > or = 10 ng/mL, and in patients with PSA between 4 and 10 ng/mL in the presence of suspicious TRU or when DPSA was > or = 0.15. The ratio of the 136 (43%) prostate cancer diagnosed relative to biopsy +/- was 1:1.32. It is concluded that early diagnosis in a selected population is useful and shows good diagnostic yield. The diagnostic algorithm used is more than acceptable with 43% positive biopsies and a good ratio between biopsy +/-. With a cutoff of 0.15 DPSA is a good method to improve PSA significance in patients in the difficult PSA range of 4 to 10 ng/mL.
authors.affiliation: Servicio de Urología, Hospital Universitario de la Princesa, Madrid.
authors.forename: R
authors.initials: R
authors.lastname: Mínguez Martínez
authors.forename: A
authors.initials: A
authors.lastname: Fernández Borrell
authors.forename: F
authors.initials: F
authors.lastname: Gómez Sancha
authors.forename: C
authors.initials: C
authors.lastname: Ruiz Zarate
authors.forename: F
authors.initials: F
authors.lastname: Teba del Pino
authors.forename: J C
authors.initials: JC
authors.lastname: Romero Tejada
authors.forename: R
authors.initials: R
authors.lastname: Arellano Gañan
authors.forename: I
authors.initials: I
authors.lastname: Pereira Sanz
mesh_terms: D000368:Aged; D000465:Algorithms; D001707:Biopsy, Needle; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000473:pathology; D014463:Ultrasonography
chemical_list: D017430:Prostate-Specific Antigen
vernacular_title: Diagnóstico precoz del cáncer de próstata en pacientes con sintomatología prostática mediante TR, PSA, ECOTR y DPSA.